TABLE 2.
N36Mut(e,g) enhances activity of gp41 NHR-directed MAbs, rendering nonneutralizing Abs neutralizing and rescuing neutralizing activity against resistant viruses
| Ab vs pseudovirus | Ab/N36Mut(e,g) combination ratio | IC50 in combination (mean ± SD)
|
Individual IC50 (mean ± SD)
|
||
|---|---|---|---|---|---|
| Ab (nM) | N36Mut(e,g) (μM) | Ab (nM) | N36Mut(e,g) (μM) | ||
| bF-3674 vs SF162 | 1:20 | 140 ± 10 | 3.1 ± 0.2 | 786 ± 67 | NAa |
| 1:40 | 106 ± 29 | 4.7 ± 1.3 | |||
| mF-3674 vs SF162 | 1:10 | 481 ± 250 | 4.8 ± 2.5 | NA | NA |
| 1:20 | 300 ± 130 | 6.0 ± 2.5 | |||
| 1:40 | 240 ± 70 | 9.5 ± 2.9 | |||
| bF-3670 vs HXB2 | 1:20 | 62 ± 9 | 1.3 ± 0.3 | NA | 5.7 ± 0.5 |
| 1:40 | 35 ± 11 | 1.4 ± 0.4 | |||
| bF-3663 vs HXB2 | 1:20 | 89 ± 14 | 1.8 ± 0.6 | NA | 5.7 ± 0.5 |
| 1:40 | 35 ± 10 | 1.4 ± 0.4 | |||
| bF-1018 vs HXB2 | 1:20 | 330 ± 130 | 1.8 ± 0.6 | NA | 5.7 ± 0.5 |
| bF-1018 vs SF162 | 1:20 | 460 ± 120 | 10 ± 3 | NA | NA |
a
NA, no detectable neutralizing activity in the range of concentrations tested [up to 1 μM for the bivalent Fabs, up to 2 μM for the monovalent Fab, and up to 20 μM for N36Mut(e,g)].